OPEN IN READ APP
COMPARATIVE STUDY
JOURNAL ARTICLE

Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials

Lorna K Henderson, Philip Masson, Jonathan C Craig, Matthew A Roberts, Robert S Flanc, Giovanni F M Strippoli, Angela C Webster
American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation 2013, 61 (1): 74-87
23182601

BACKGROUND: Lupus nephritis accounts for ~1% of patients starting dialysis therapy. Treatment regimens combining cyclophosphamide with steroids preserve kidney function but have significant side effects. Newer immunosuppressive agents may have improved toxicity profiles.

STUDY DESIGN: Systematic review and random-effects meta-analysis, searching MEDLINE (1966 to April 2012), EMBASE (1988-2011), and the Cochrane Renal Group Specialised Register.

SETTING & POPULATION: Patients with biopsy-proven proliferative lupus nephritis (classes III, IV, V+III, and V+IV).

SELECTION CRITERIA: Randomized controlled trials.

INTERVENTION: Immunosuppressive treatment regimens used for induction and maintenance therapy of lupus nephritis.

OUTCOMES: Mortality, renal remission and relapse, doubling of creatinine level, proteinuria, incidence of end-stage kidney disease, ovarian failure, alopecia, leukopenia, infections, diarrhea, vomiting, malignancy, and bladder toxicity.

RESULTS: 45 trials (2,559 participants) of induction therapy and 6 (514 participants) of maintenance therapy were included. In induction regimens comparing mycophenolate mofetil (MMF) with intravenous cyclophosphamide, there was no significant difference in mortality (7 studies, 710 patients; risk ratio [RR], 1.02; 95% CI, 0.52-1.98), incidence of end-stage kidney disease (3 studies, 231 patients; RR, 0.71; 95% CI, 0.27-1.84), complete renal remission (6 studies, 686 patients; RR, 1.39; 95% CI, 0.99-1.95), and renal relapse (1 study, 140 patients; RR, 0.97; 95% CI, 0.39-2.44). MMF-treated patients had significantly lower risks of ovarian failure (2 studies, 498 patients; RR, 0.15; 95% CI, 0.03-0.80) and alopecia (2 studies, 522 patients; RR, 0.22; 95% CI, 0.06-0.86). In maintenance therapy comparing azathioprine with MMF, the risk of renal relapse was significantly higher (3 studies, 371 patients; RR, 1.83; 95% CI, 1.24-2.71).

LIMITATIONS: Heterogeneity in interventions and definitions of remission and lack of long-term outcome reporting.

CONCLUSIONS: MMF is as effective as cyclophosphamide in achieving remission in lupus nephritis, but is safer, with a lower risk of ovarian failure. MMF is more effective than azathioprine in maintenance therapy for preventing relapse, with no difference in clinically important side effects.

Discussion

You are not logged in. Sign Up or Log In to join the discussion.

Responses

Sort by: Most RecentHighest Rated

Daniel Schwartz

This meta-analysis supports MMF as the optimal induction and maintenance agent for lupus nephritis.

3

Related Papers

Available on the App Store

Available on the Play Store
Remove bar
Read by QxMD icon Read
23182601
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"